Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.